Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease (NT-proBNP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01801722|
Recruitment Status : Completed
First Posted : March 1, 2013
Last Update Posted : March 7, 2018
|Condition or disease|
|Chronic Obstructive Pulmonary Disease Chronic Heart Failure|
Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.
- An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
- Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
- Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
- Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.
|Study Type :||Observational|
|Actual Enrollment :||75 participants|
|Official Title:||Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||June 2008|
NT-proBNP,ejection fraction ,COPD stage.
The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
- Percentage of patients with elevated NT-proBNP. [ Time Frame: 3 months ]NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.
- Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography. [ Time Frame: 3 months ]Echocardiography was performed once in each referred patient. Three months was a period of data collection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801722
|Primary health care center.|
|Olofström, Blekinge, Sweden, 29332|
|Principal Investigator:||Elzbieta Kaszuba, PhD student||Lund University|